{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:34:23Z","timestamp":1769729663906,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jacc.2018.01.006","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T17:30:57Z","timestamp":1519666257000},"page":"1005-1008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treating Gout in Patients With Cardiovascular Disease"],"prefix":"10.1016","volume":"71","author":[{"given":"Michael M.","family":"Givertz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2018.01.006_bib1","unstructured":"Brainyquotes. Thomas Sydenham quotes. Available at: https:\/\/www.brainyquote.com\/quotes\/thomas_sydenham_273073. Accessed January 5,\u00a02018."},{"key":"10.1016\/j.jacc.2018.01.006_bib2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.7326\/0003-4819-54-3-452","article-title":"Identification of urate crystals in gouty synovial fluid","volume":"54","author":"McCarty","year":"1961","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2018.01.006_bib3","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jacc.2018.01.006_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: a systematic review and meta-analysis","volume":"16","author":"Huang","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2018.01.006_bib5","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1161\/CIRCULATIONAHA.115.016379","article-title":"Xanthine oxidase inhibitors in heart failure: where do we go from here?","volume":"131","author":"Tamariz","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.006_bib6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jacc.2017.12.052","article-title":"Cardiovascular risks of probenecid versus allopurinol in older patients with gout","volume":"71","author":"Kim","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.006_bib7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1161\/HYPERTENSIONAHA.116.08488","article-title":"Effect of uric acid-lowering agents on endothelial function: a randomized, double-blind, placebo-controlled trial","volume":"69","author":"Borgi","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2018.01.006_bib8","doi-asserted-by":"crossref","first-page":"H574","DOI":"10.1152\/ajpheart.00854.2013","article-title":"Novel role of transient receptor potential vanilloid 2 in the regulation of cardiac performance","volume":"306","author":"Rubinstein","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2018.01.006_bib9","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1083\/jcb.200301101","article-title":"A\u00a0novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor-regulated channel","volume":"161","author":"Iwata","year":"2003","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.jacc.2018.01.006_bib10","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.112.196980","article-title":"Uric acid reduction rectifies prehypertension in obese adolescents","volume":"60","author":"Soletsky","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2018.01.006_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.117.10251","article-title":"Probenecid inhibits alpha-adrenergic receptor-mediated vasoconstriction in the human leg vasculature","volume":"71","author":"Nyberg","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2018.01.006_bib12","doi-asserted-by":"crossref","first-page":"H1208","DOI":"10.1152\/ajpheart.00251.2012","article-title":"Cardiomyocyte ATP release through pannexin 1 aids in early fibroblast activation","volume":"303","author":"Dolmatova","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2018.01.006_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.brainres.2016.05.002","article-title":"Probenecid protects against oxygen-glucose deprivation injury in primary astrocytes by regulating inflammasome activity","volume":"1643","author":"Jian","year":"2016","journal-title":"Brain Res"},{"key":"10.1016\/j.jacc.2018.01.006_bib14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.01.006_bib15","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","article-title":"High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid","volume":"114","author":"George","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.01.006_bib16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000360609","article-title":"Effects of allopurinol on endothelial dysfunction: a meta-analysis","volume":"39","author":"Kanbay","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2018.01.006_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2015.01.013","article-title":"Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study","volume":"128","author":"Kim","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2018.01.006_bib18","first-page":"393","article-title":"Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor","volume":"10","author":"Foody","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.jacc.2018.01.006_bib19","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","article-title":"Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims","volume":"75","author":"Solomon","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacc.2018.01.006_bib20","unstructured":"U.S. Food and Drug Administration. Uloric (febuxostat): Drug Safety Communication \u2013 FDA to Evaluate Increased Risk of Heart-Related Death. November 15, 2017. Available at: https:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm585281.htm. Accessed January 3, 2018."},{"key":"10.1016\/j.jacc.2018.01.006_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005354","article-title":"Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia","volume":"4","author":"MacDonald","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2018.01.006_bib22","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","article-title":"Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study","volume":"51","author":"Hare","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.01.006_bib23","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718300330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718300330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:14:41Z","timestamp":1760015681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109718300330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0735109718300330"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2018.01.006","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating Gout in Patients With Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2018.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2017.12.052","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}